European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients
Article first published online: 23 JAN 2014
© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 105, Issue 1, pages 105–109, January 2014
Total views since publication: 293
How to Cite
Cancer Sci 105 (2014) 105–109
- Issue published online: 24 JAN 2014
- Article first published online: 23 JAN 2014
- Accepted manuscript online: 8 NOV 2013 11:23AM EST
- Manuscript Accepted: 5 NOV 2013
- Manuscript Revised: 25 OCT 2013
- Manuscript Received: 16 SEP 2013
- Chronic myeloid leukemia;
- European Treatment and Outcome Study score;
- Hasford score;
- Sokal score;
The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, a new European Treatment and Outcome Study (EUTOS) scoring system was developed. We performed a multicenter retrospective study to validate the effectiveness of each of the three scoring systems. The study cohort included 145 patients diagnosed with CML in chronic phase who were treated with imatinib. In the EUTOS low- and high-risk groups, the cumulative incidence of complete cytogenetic response (CCyR) at 18 months was 86.9% and 87.5% (P = 0.797) and the 5-year overall survival rate was 92.6% and 93.3% (P = 0.871), respectively. The cumulative incidence of CCyR at 12 months, 5-year event-free survival and 5-year progression-free survival were not predicted using the EUTOS scoring system. However, there were significant differences in both the Sokal score and Hasford score risk groups. In our retrospective validation study, the EUTOS score did not predict the prognosis of patients with CML in chronic phase treated with imatinib.